标题
Treatment landscape of metastatic pancreatic cancer
作者
关键词
Pancreatic cancer, Precision medicine, Biomarkers, FOLFIRINOX, Gemcitabine, Nab-paclitaxel, Liposomal-irinotecan
出版物
CANCER TREATMENT REVIEWS
Volume 96, Issue -, Pages 102180
出版商
Elsevier BV
发表日期
2021-03-18
DOI
10.1016/j.ctrv.2021.102180
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Alliance A021501: Preoperative mFOLFIRINOX or mFOLFIRINOX plus hypofractionated radiation therapy (RT) for borderline resectable (BR) adenocarcinoma of the pancreas.
- (2021) Matthew H. G. Katz et al. JOURNAL OF CLINICAL ONCOLOGY
- Cancer statistics, 2020
- (2020) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Randomized Phase III Study of FOLFOX Alone and with Pegilodecakin as Second-line Therapy in Patients with Metastatic Pancreatic Cancer (SEQUOIA).
- (2020) J. Randolph Hecht et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline BRCA/PALB2 Mutation
- (2020) Eileen M. O’Reilly et al. JOURNAL OF CLINICAL ONCOLOGY
- Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial
- (2020) Michael J Pishvaian et al. LANCET ONCOLOGY
- Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution
- (2020) Michelle Chan-Seng-Yue et al. NATURE GENETICS
- Real-World Dosing Patterns and Outcomes of Patients With Metastatic Pancreatic Cancer Treated With a Liposomal Irinotecan Regimen in the United States
- (2020) Afsaneh Barzi et al. PANCREAS
- The impact of metastatic sites in advanced pancreatic adenocarcinoma, systematic review and meta-analysis of prospective randomized studies
- (2020) Pedro Luiz Serrano Usón et al. PLoS One
- ESPAC-5F: Four-arm, prospective, multicenter, international randomized phase II trial of immediate surgery compared with neoadjuvant gemcitabine plus capecitabine (GEMCAP) or FOLFIRINOX or chemoradiotherapy (CRT) in patients with borderline resectable pancreatic cancer.
- (2020) Paula Ghaneh et al. JOURNAL OF CLINICAL ONCOLOGY
- Multicenter Retrospective Analysis of Second-Line Therapy after Gemcitabine Plus Nab-Paclitaxel in Advanced Pancreatic Cancer Patients
- (2020) Valeria Merz et al. Cancers
- Plasma IL8 Is a Biomarker for TAK1 Activation and Predicts Resistance to Nanoliposomal Irinotecan in Patients with Gemcitabine-Refractory Pancreatic Cancer
- (2020) Valeria Merz et al. CLINICAL CANCER RESEARCH
- Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma
- (2020) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- LBA65 The Canadian Cancer Trials Group PA.7 trial: Results of a randomized phase II study of gemcitabine (GEM) and nab-paclitaxel (Nab-P) vs GEM, nab-P, durvalumab (D) and tremelimumab (T) as first line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC)
- (2020) D.J. Renouf et al. ANNALS OF ONCOLOGY
- KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Patients with Colorectal Cancer (CRC) and Other Solid Tumors Harboring a KRAS G12C Mutation
- (2020) M.L. Johnson et al. EUROPEAN JOURNAL OF CANCER
- KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors
- (2020) David S. Hong et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cancer statistics, 2019
- (2019) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Targeting the untargetable KRAS in cancer therapy
- (2019) Pingyu Liu et al. Acta Pharmaceutica Sinica B
- Drug resistance in pancreatic cancer: New player caught in act
- (2019) Gabriele Capurso et al. EBioMedicine
- Cytosolic 5′-nucleotidase 1A is overexpressed in pancreatic cancer and mediates gemcitabine resistance by reducing intracellular gemcitabine metabolites
- (2019) Melanie S. Patzak et al. EBioMedicine
- Liposomal irinotecan and 5-fluorouracil/leucovorin in older patients with metastatic pancreatic cancer – A subgroup analysis of the pivotal NAPOLI-1 trial
- (2019) Teresa Macarulla et al. Journal of Geriatric Oncology
- Molecular subtypes of pancreatic cancer
- (2019) Eric A. Collisson et al. Nature Reviews Gastroenterology & Hepatology
- NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors
- (2019) Andrea Wang-Gillam et al. EUROPEAN JOURNAL OF CANCER
- Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of AMG 510, a novel small molecule KRASG12C inhibitor, in advanced solid tumors.
- (2019) Marwan Fakih et al. JOURNAL OF CLINICAL ONCOLOGY
- Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer
- (2019) Talia Golan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nomogram for Predicting Survival in Patients Treated with Liposomal Irinotecan Plus Fluorouracil and Leucovorin in Metastatic Pancreatic Cancer
- (2019) Chen et al. Cancers
- Current Clinical Strategies of Pancreatic Cancer Treatment and Open Molecular Questions
- (2019) Maximilian Brunner et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Hereditary gastrointestinal cancers: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
- (2019) N Stjepanovic et al. ANNALS OF ONCOLOGY
- Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study
- (2019) Aurelien Marabelle et al. JOURNAL OF CLINICAL ONCOLOGY
- Cetuximab in Pancreatic Cancer Therapy: A Systematic Review and Meta-Analysis
- (2019) Tobias Forster et al. ONCOLOGY
- Real‐world outcomes of FOLFIRINOX vs gemcitabine and nab‐paclitaxel in advanced pancreatic cancer: A population‐based propensity score‐weighted analysis
- (2019) Kelvin K. W. Chan et al. Cancer Medicine
- Liposomal Irinotecan + 5-FU/LV in Metastatic Pancreatic Cancer
- (2019) Teresa Macarulla Mercadé et al. PANCREAS
- Results from the prospective German TPK clinical cohort study: Treatment algorithms and survival of 1,174 patients with locally advanced, inoperable or metastatic pancreatic ductal adenocarcinoma
- (2018) Susanna Hegewisch-Becker et al. INTERNATIONAL JOURNAL OF CANCER
- Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries
- (2018) Claudia Allemani et al. LANCET
- Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
- (2018) Alexander Drilon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune therapies in pancreatic ductal adenocarcinoma: Where are we now?
- (2018) Marc Hilmi et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Organoid profiling identifies common responders to chemotherapy in pancreatic cancer
- (2018) Hervé Tiriac et al. Cancer Discovery
- Targeted therapies in the management of locally advanced and metastatic pancreatic cancer: a systematic review
- (2018) Anjali V. Sheahan et al. Oncotarget
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- 664PPhase I/II study of single agent MCLA-128, a full length IgG1 bispecific antibody targeting the HER3 pathway: Overall safety at the recommended phase II dose (R2PD) and preliminary activity in HER2+ metastatic gastric/gastroesophageal junction cancer (GC/GEJ)
- (2018) M Alsina et al. ANNALS OF ONCOLOGY
- Quality of life in metastatic pancreatic cancer patients receiving liposomal irinotecan plus 5-fluorouracil and leucovorin
- (2018) Richard A. Hubner et al. EUROPEAN JOURNAL OF CANCER
- Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes
- (2018) Andrew McGuigan et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial
- (2017) John P Neoptolemos et al. LANCET
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
- (2017) Dung T. Le et al. SCIENCE
- nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: a subgroup analysis of the Western European cohort of the MPACT trial
- (2017) Josep Tabernero et al. OncoTargets and Therapy
- More deaths from pancreatic cancer than breast cancer in the EU by 2017
- (2016) J. Ferlay et al. ACTA ONCOLOGICA
- PANCREOX: A Randomized Phase III Study of Fluorouracil/Leucovorin With or Without Oxaliplatin for Second-Line Advanced Pancreatic Cancer in Patients Who Have Received Gemcitabine-Based Chemotherapy
- (2016) Sharlene Gill et al. JOURNAL OF CLINICAL ONCOLOGY
- Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial
- (2016) Andrea Wang-Gillam et al. LANCET
- KRAS Mutant Pancreatic Cancer: No Lone Path to an Effective Treatment
- (2016) Daniel Zeitouni et al. Cancers
- Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort
- (2015) Alix Portal et al. BRITISH JOURNAL OF CANCER
- Family history as a marker of platinum sensitivity in pancreatic adenocarcinoma
- (2015) David Fogelman et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial
- (2015) D. Goldstein et al. JNCI-Journal of the National Cancer Institute
- nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial
- (2015) D. Goldstein et al. JNCI-Journal of the National Cancer Institute
- Second-Line Oxaliplatin, Folinic Acid, and Fluorouracil Versus Folinic Acid and Fluorouracil Alone for Gemcitabine-Refractory Pancreatic Cancer: Outcomes From the CONKO-003 Trial
- (2014) Helmut Oettle et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant Chemotherapy With Gemcitabine and Long-term Outcomes Among Patients With Resected Pancreatic Cancer
- (2013) Helmut Oettle et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
- (2013) Daniel D. Von Hoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Computational Modeling of Pancreatic Cancer Reveals Kinetics of Metastasis Suggesting Optimum Treatment Strategies
- (2012) Hiroshi Haeno et al. CELL
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- (2011) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now